Failure to Document Timely Physician Response to Pharmacy Drug Regimen Reviews
Summary
The facility failed to ensure that physician or prescriber responses to monthly pharmacy drug regimen review recommendations were documented in a timely manner for three of five sampled residents. The report states that the licensed pharmacist was to perform monthly drug regimen reviews, including review of the medical chart, and that the facility did not provide the pharmacy review policy when requested during the survey. The Director of Nursing said she did not know whether the pharmacy reviews had been addressed by the physician, and the Administrator said she expected the pharmacy reviews to be completed monthly and the physician/provider to review the recommendations. For one resident with schizoaffective disorder, the chart contained pharmacy recommendations regarding psychotropic medications, including quetiapine and ramelteon, with requests for gradual dose reduction consideration. The forms were blank and unsigned by the physician/prescriber, and the progress notes showed no documentation that the physician was made aware of the pharmacy review and recommendations. The resident’s care plan identified use of psychotropic medications and included consultation with pharmacy and the MD to consider dosage reduction at least quarterly. For a second resident with anxiety, depression, PTSD, and bipolar disorder-related psychotropic use, the pharmacy review noted PRN lorazepam orders and stated that PRN psychotropic orders cannot exceed 14 days unless the prescriber documents the rationale and duration. One review was signed by the physician, but no duration or rationale was documented for use beyond 14 days. A later review was blank and unsigned, and the progress notes showed no documentation of the physician’s duration or rationale for the medication. For a third resident with spastic quadriplegic cerebral palsy, dysphagia, depression, and hospice care, the pharmacy review requested clarification of a morphine order strength and identified duplicate therapy involving erythromycin ophthalmic ointment and TobraDex ophthalmic medication. One later review was signed with handwritten changes, but another was blank and unsigned. The MAR showed the morphine and erythromycin ophthalmic medications were administered, and the progress notes contained no documentation related to those medications during the reviewed period.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.